Wordt geladen...
Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSO(TM)), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer (NSCLC), limits the long‐term benefits for patients. Thus, effective t...
Bewaard in:
| Gepubliceerd in: | Mol Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7138398/ https://ncbi.nlm.nih.gov/pubmed/32003107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12645 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|